DOH Resumes AstraZeneca Vaccination To All Age Groups

The Department of Health (DOH) has postponed AstraZeneca vaccination in peopled aged 60 and below, citing that the rare incidences of blood clotting occur in the younger population. What do experts say about the potential blood clots side-effects after getting the AstraZeneca vaccine?

Reports of “thrombotic incidences” after AstraZeneca shot poured in from several countries

By now, many people understand that receiving any type of COVID-19 vaccine can trigger mild side-effects, such as pain in the injection site and mild fever. The possibility of a severe allergic reaction, while rare, is also there.

But blood clots paint a completely different picture.

In the first week of March¹, Austrian authorities reported the death of a 49-year old woman due to a “severe coagulation disorder.” The disorder took place after she received the AstraZeneca vaccine. Later, the authorities revealed another incident: a 35-year old man vaccinated with the same vaccine is now recovering after having blood clots in his lungs.

From two incidences in Austria, reports of thrombotic incidences after an AstraZeneca shot came pouring in from different countries, like Norway and Denmark.

Update:

Denmark has now completely stopped their AstraZeneca vaccine roll-out.

Norwegian authorities² even detailed that they treated three people for “cerebral hemorrhages and severe blood clots” after getting vaccinated. These people, they highlighted, were all of “younger age.”

On March 11, The European Medicines Agency (EMA) cited³ 30 cases of thrombotic events among almost 5 million people in the European Economic Area who had the AstraZeneca vaccine.

Update:

In their latest statement, EMA said the benefits of AstraZeneca, now called Vaxevria, continue to outweigh the risks in all age groups. However, “very rare cases” of blood clotting with low platelet count may occur after vaccination.

WHO: No association between thrombotic incidences and AstraZeneca vaccine

On March 16, the World Health Organization’s chief scientist, Soumya Swaminathan, emphasized⁴ that, so far, they do not see a connection between the potential blood clots side-effects and the AstraZeneca vaccine.

For this reason, they urge the countries not to halt their vaccine rollout.

To date, Thailand has announced that they will be pushing through with their vaccination program using AstraZeneca despite delaying it before due to safety concerns. Indonesia, on the other hand, delayed its rollout until further notice.

AstraZeneca: “The number of thrombotic incidences was small.”

AstraZeneca continues to assure the people of their vaccine’s safety based on “clear scientific evidence.” The data they gathered from 200 million people who received the vaccine also showed that the occurrences of blood clots with low platelet are “very rare.”

Despite this, the company behind AstraZeneca believes that the safety of the public should always come first; hence, they are keeping the issue under close review.

Update:

In their most recent post, AstraZeneca said that regulating agencies see a connection between the vaccine and blood clots with low platelet. For this reason, the agencies requested them to list the incidence as an “extremely rare potential side-effect.”

The Philippines halts AstraZeneca vaccine rollout to people aged 60 and below

The Department of Health (DOH) and the Food and Drug Administration (FDA) are aware that some countries have paused their AstraZeneca vaccine rollout due to the reports of potential blood clots side-effects.

To date, the Department has suspended AstraZeneca vaccination to peopled aged 60 and below, following reports of blood clotting incidences with low platelet in younger population. The suspension, according to officials, is temporary, as they  further evaluate the vaccine.

Update:

The DOH resumes AstraZeneca rollout to all age groups.

Key Takeaways

Find more of the latest health news here.